Biology, genetics and imaging of glial cell tumours

C WALKER, BSc, PhD, A BABORIE, FRCPath, D CROOKS, FRCPATH, S WILKINS, MRCPCH and

M D JENKINSON, PhD, FRCSEd (NEURO.SURG)

The Walton Centre for Neurology and Neurosurgery, Liverpool, UK, and Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK

ABSTRACT. Despite advances in therapy, gliomas remain associated with poor prognosis. Clinical advances will be achieved through molecularly targeted biological therapies, for which knowledge of molecular genetic and gene expression characteristics in relation to histopathology and in vivo imaging are essential. Recent research supports the molecular classification of gliomas based on genetic alterations or gene expression profiles, and imaging data supports the concept that molecular subtypes of glioma may be distinguished through non-invasive anatomical, physiological and metabolic imaging techniques, suggesting differences in the baseline biology of genetic subtypes of infiltrating glioma. Furthermore, MRI signatures are now being associated with complex gene expression profiles and cellular signalling pathways through genome-wide microarray studies using samples obtained by image guidance which may be co-registered with clinical imaging. In this review we describe the pathobiology, molecular pathogenesis, stem cells and imaging characteristics of gliomas with emphasis on astrocytomas and oligodendroglial neoplasms.

Gliomas are the most common primary central nervous system tumour and, although they represent only 2% of cancers, their treatment presents one of the greatest challenges to oncologists. Despite advances in therapy these tumours remain associated with high morbidity and mortality and, compared with other cancers, account for the greatest number of average years of life lost to cancer [1]. Infiltrative gliomas are incurable and the prognostic outlook remains poor, with low-grade tumours likely to progress and short survival, frequently less than a year, for many patients with high-grade glioma (HGG). Median survival with currently available therapies remains much less than 2 years for the most aggressive form, glioblastoma multiforme (GBM), which accounts for 60–70% of gliomas [2].

The causes of treatment failure, disease progression and recurrence arise from the fundamental biology of gliomas, challenging the biologist to advance our understanding of the genetic aberrations and cellular mechanisms that dictate tumour behaviour and provide better diagnostic tools and new biologically targeted therapies [3–7]. In the same way, development of advanced multimodal magnetic resonance (MR) and positron emission tomography (PET) imaging has allowed non-invasive characterisation of the physiology and metabolism of these tumours, leading to improved diagnosis and prognostication and better discrimination between treatment effects and tumour recurrence [8–11]. In many recent research studies, attempts are being made to correlate features of imaging with the genetics and biology of the tumour tissues giving rise to these imaging signatures [12–14]. This review provides an overview of the pathobiology and molecular genetics of gliomas, with focus on diffusely infiltrating astrocytomas and oligodendroglial neoplasms and describes imaging characteristics in relation to biology and genetics in these tumours.

Pathological features of gliomas

Gliomas are histologically heterogeneous tumours often diagnosed from small tissue specimens, which may be prone to sampling error unless obtained using imaging techniques to guide biopsy or sampling during resection. Early tumour classifications relied on comparing tumour features with those of normal tissue. Thus brain tumours with cells resembling astrocytes were termed astrocytomas and those with cells resembling oligodendrocytes were called oligodendrogliomas. Although historically a number of classification schemes have been used [15], currently the most widely used classification and grading system is that of the World Health Organization (WHO) [16]. The WHO classification is based on histological features including cellularity, mitotic activity, nuclear atypia, vascularity and necrosis. It also recognises four prognostic grades and a variety of histological subtypes of which astrocytomas (60–70%), oligodendrogliomas (10–30%) and ependymomas (<10%) are the most common (Figure 1). A variety of other histopathology types, e.g. gangliogliomas and gangliocytomas, are less commonly encountered. However, irrespective of the classification system used, the small sample size and subjective criteria means that for many gliomas diagnosis may be difficult and subject to inter-and intraobserver variation [17, 18].

Pilocytic astrocytomas correspond to WHO grade I and are relatively circumscribed, slow growing, often
cystic astrocytomas comprising 5–6% of all gliomas and show contrast enhancement on MRI [19, 20]. They are most common in children and young adults, in whom the majority arise in the cerebellum, hypothalamus and third ventricular region and are usually curable by surgical excision. The common gliomas that arise in the cerebral hemispheres are called “diffuse” gliomas because of their marked propensity to infiltrate the surrounding brain parenchyma, irrespective of grade. These migratory cells are refractory to conventional therapy and may contribute to treatment failure [21]. Diffuse astrocytomas include astrocytomas of WHO grades II, III and IV. Astrocytomas WHO grade II represent 10–15% of all astrocytic tumours, have a peak incidence in adults between 30 and 40 years, show a predominance in males, are more common supratentorially and rare in the cerebellum. These tumours consist of well-differentiated fibrillary or gemistocytic astrocytes on a background of loosely structured, often microcystic, matrix. Compared with normal brain, there is moderately increased cellularity and occasional nuclear atypia, but mitotic activity is generally absent [22]. Diffuse astrocytomas WHO grade II show hypointensity on T1 weighted and hyperintensity on T2 weighted MRI and rarely show gadolinium enhancement [9]. Gliomas of grades I and II are termed low grade and often considered “benign”, although this may be misleading as some show rapid clinical evolution.

HGGs include grades III and IV, are more aggressive and are often referred to as “malignant”, although metastasis outside the central nervous system is exceedingly rare. Low-grade astrocytomas have an inherent tendency to undergo transformation to more aggressive high-grade tumours, associated with loss of cell cycle control and increased angiogenesis. WHO grade III astrocytomas show increased cellularity, mitotic activity and nuclear atypia, becoming more atypical with progressive anaplasia [23]. Anaplastic astrocytomas are likely to show patchy contrast enhancement on MRI or CT due to blood–brain barrier breakdown associated with vascular proliferation, and bright T2 signal due to oedema [9, 24]. Glioblastoma, WHO grade IV, is the most common form of astrocytic tumour and accounts for 60–75% of astrocytic tumours, affecting predominantly adults with a peak incidence between 45 and 75 years of age and occurring most commonly in the subcortical white matter of the cerebral hemispheres. Glioblastoma is an anaplastic cellular glioma with pleomorphic astrocytic cells with marked nuclear atypia and high mitotic rates. Glioblastomas are rapidly evolving tumours typically with neoplastic infiltration of adjacent normal brain tissue and solid proliferating tumour at the periphery. The rapid tumour growth results in spontaneous necrosis with pseudopalisading of tumour cells, quickly developing a necrotic tumour core. The essential diagnostic features that distinguish glioblastomas

**Figure 1.** World Health Organization (WHO) histopathology classification of gliomas. (a) Pilocytic astrocytoma WHO grade I, with compact bundles of “piloid”-elongated cells containing nuclei with minimal atypia; (b) astrocytoma WHO grade II, showing increased cellularity with occasional atypical nuclei and some cells with enlarged cytoplasm; (c) astrocytoma WHO grade III, containing darkly stained nuclei with increased cytoplasm and occasional mitoses; (d) glioblastoma WHO grade IV, illustrating tumour necrosis without pseudopalisading as is commonly seen in glioblastomas; (e) oligodendroglioma WHO grade II, showing perinuclear haloes, “chickenwire” vasculature and microcalcification; (f) oligodendroglioma WHO grade III, with increased cellularity retaining roundness of nuclei associated with cell necrosis, note the mild infiltration by neutrophils.
from lower grade gliomas are prominent endothelial proliferation forming multilayered vessels and/or necrosis [25, 26]. On neuroimaging, glioblastomas commonly show extensive peritumoural oedema and marked peripheral gadolinium enhancement, indicating viable tumour surrounding extensive central necrosis, and marked mass effect secondary to vasogenic oedema [9, 24]. Variants of glioblastoma include giant cell glioblastoma displaying numerous multinucleated tumour cells, gliosarcoma with regions of glial and mesenchymal differentiation, small cell glioblastomas with highly monomorphic small densely packed round cells and glioblastomas with an oligodendrogial component that contains foci that resemble oligodendroglialomas [25, 27]. Although primary and secondary glioblastomas are morphologically identical, primary glioblastomas arise de novo with a short clinical history (usually <3 months) without evidence of an earlier precursor lesion, typically in an older population. In contrast, secondary glioblastomas are less frequent (<10% of glioblastomas), progress over a period of years from an earlier lower grade astrocytoma and are more common in younger patients [28, 29].

Oligodendroglial tumours include oligodendrogliomas and oligoastrocytomas and the WHO classification recognises two malignancy grades, namely grades II and III. Compared with astrocytomas, oligodendrogial tumours are more likely to have an indolent clinical course and to be chemosensitive [30–32]. Historically, oligodendrogial tumours account for 5–6% of all gliomas, but their reported incidence has risen in recent years, possibly owing to less stringent diagnostic criteria and the recognition of the clinical need to distinguish oligodendrogliomas from astrocytomas [33–36]. Oligodendrogliomas arise, with a peak incidence between 40 and 45 years of age, commonly in the cortex and white matter of the cerebral hemispheres, with 50–60% in the frontal lobes [37]. The distinguishing feature of these tumours is their uniform round nuclei with clear perinuclear halos, which result as an artefact of fixation, and the delicate branching patterns of their vasculature that resemble “chicken wire” [38, 39]. Oligodendroglioma WHO grade II are diffusely infiltrating, well-differentiated tumours with moderate cellularity, occasional mitoses and nuclear atypia [39]. On neuroimaging, grade II oligodendrogliomas show hypointensity on T1 weighted and hyperintensity on T2 weighted MRI and frequently display calcification on CT, although this is not diagnostic [40]. Approximately 50% of grade II oligodendrogliomas show diffuse contrast enhancement [41, 42]. In addition to rounded hyperchromatic nuclei, perinuclear halos and a network of branching vasculature, anaplastic oligodendrogliomas (WHO grade III) exhibit increased cellularity, mitotic activity and prominent microvascular proliferation and/or necrosis [43]. On imaging, they show heterogeneous patterns, owing to variable extents of cystic degeneration, haemorrhage, necrosis and calcification; contrast enhancement is usual but peripheral enhancement is uncommon [40]. Oligoastrocytomas are mixed gliomas with neoplastic cells that phenotypically resemble tumour cells in oligodendrogliomas or astrocytomas present either in discrete regions or diffusely admixed throughout the tumour [44] (Figure 2). Compared with WHO grade II oligoastrocytomas, anaplastic oligoastrocytomas (WHO grade III), have increased cellularity, mitotic activity, nuclear atypia and microvascular proliferation, but since the revision of the WHO classification system in 2007, those with necrosis are considered glioblastomas with an oligodendrogial component [26, 45]. Anaplastic oligodendrogliomas and oligoastrocytomas may arise either de novo or through progression from a lower grade tumour [46]. Gliomas display a spectrum of morphological appearances ranging from those with classic features of pure oligodendroglioma at one extreme to typical astrocytomas at the other, resulting in a diagnostic challenge for all but the classic oligodendrogliomas and astrocytomas and considerable variation between pathologists; diagnosis of these gliomas remains controversial [18, 38]. Therefore, in order to minimise errors and maximise treatment effects, a multidisciplinary approach is needed integrating clinical, neuroradiological, histological and molecular genetic data on individual patient’s biopsies to reach a final diagnosis.

**Molecular pathogenesis**

It is now recognised the classification of gliomas based on genetic alterations or gene expression profiles may act as an adjunct to histopathological diagnosis and in some instances more closely correlates with prognosis than histopathology assessment [33, 47–50]. Indeed a single histological subtype may encompass more than one molecular subtype, each with different prognoses. Development of gliomas and their malignant transformation results from sequential accumulation of genetic alterations [4, 7, 48, 51] (Figure 3). Genetic changes found in gliomas include amplification and/or overexpression of oncogenes and loss of tumour suppressor genes and DNA repair genes through mutation, loss of heterozygosity (LOH) or by epigenetic mechanisms such as promoter hypermethylation. These genetic changes result

---

**Figure 2. Oligoastrocytomas. (a)** Oligoastrocytoma World Health Organization (WHO) grade II showing a moderately cellular glioma composed of an oligodendrogial (left aspect) and an astrocytic component (right aspect) with calcification. **(b)** Oligoastrocytoma WHO grade III showing densely packed diffuse oligodendrogial and astrocytic cells with scattered mitoses.
progressively in uncontrolled proliferation and loss of normal cell cycle control mechanisms, diminished ability to undergo apoptosis in response to genotoxic agents, failure of DNA repair mechanisms, increasing genetic instability and deregulation of growth factor signalling pathways. The molecular pathogenesis differs between adult and paediatric gliomas, as does the incidence of the various forms of glioma.

**Adult gliomas**

TP53 mutation is by far the most common genetic alteration in adult diffuse astrocytomas WHO grade II, accompanied by LOH of the other allele at 17p13 in over 60% of these tumours [48, 52], affecting the G1 cell cycle checkpoint. Low-grade astrocytomas show overexpression of platelet-derived growth factor (PDGF) ligands and receptors, which may stimulate cell proliferation [48, 53]. Additional genetic changes seen in a proportion of these tumours include LOH of 22q and gain of chromosome 7 and amplification of 8q [48, 54]. Progression to anaplasia is accompanied by a variety of genetic changes in genes that regulate the G1 cell cycle checkpoint, such that this control point is aberrant in all high-grade astrocytomas. These genetic changes include TP53 mutation, retinoblastoma gene (Rb1) mutation, deletion of CDKN2A or CDKN2B, which code for the negative regulators of G1 to S phase cell progression p16INK4A and p15INK4b, and cyclin-dependent kinase (CDK) 4 and CDK6 amplification. Other genetic deletions in addition to 17p and 22q may include deletions on chromosomes 6, 9p, 11p and 19q [48]. LOH 10q and phosphatase and tensin homologue on chromosome 10 (PTEN) mutation, both of which are associated with poor prognosis [55, 56] are seen in 35–60% and 18–23% of anaplastic astrocytomas respectively [55, 57–59]. Glioblastomas exhibit the greatest variety of genetic alterations and these can be used to distinguish between glioblastomas that have progressed from an earlier astrocytoma (secondary glioblastomas) and those that have arisen de novo [25, 29, 48]. Secondary glioblastomas are likely to have TP53 mutation (65%), loss of 17p, overexpression of PDGF receptor (PDGFR), abnormalities in the p16 and Rb1 pathways and LOH 10q. Glioblastomas that arise de novo are characterised by epidermal growth factor receptor (EGFR) amplification, genetic alterations that disrupt cell cycle control, such as p14ARF or p16INK4a.

**Figure 3.** Molecular pathogenesis of adult astrocytic and oligodendrogialneoplasms. The illustration shows the progression of low-grade astrocytomas and oligodendrogliomas to higher grade with sequential accumulation of genetic alterations and impact on the biological properties of these tumours. Genetic alterations seen in lower grade tumours are retained on progression. Anaplastic oligodendrogliomas may arise through progression or de novo, but irrespective of route have similar clinical behaviour and molecular genetic characteristics with 1p/19q loss as their genetic hallmark. Glioblastomas arise de novo or progress from lower grade astrocytomas. Although indistinguishable clinically, they may be separated by their spectrum of genetic alterations, but these genetic alterations are not mutually exclusive to either lineage. The most common genetic alterations used to distinguish molecular subtypes of glioma are shown in red. All, astrocytoma WHO grade II; AII, astrocytoma WHO grade III; amp, amplification; del, deletion; GBM, glioblastoma WHO grade IV; meth, methylation; mut, mutation; OII, oligodendroglioma WHO grade II; OIII, oligodendroglioma WHO grade III. OE, overexpression.
deletions or MDM2 and MDM4 amplification or over-expression and infrequently TP53 mutation. LOH of 10q and 10p resulting in complete loss of one copy of chromosome 10 and deletions or mutations in the PTEN gene that negatively regulates the PI3K kinase pathway are also likely [25, 48, 60]. Although distinct genetic alterations may be used to distinguish primary and secondary glioblastomas, these changes are not mutually exclusive and similar molecular pathways are affected.

EGFR is a transmembrane protein responsible for transmission of signal from its extracellular ligands, epidermal growth factor (EGF) and tumour necrosis factor alpha (TNF-α) through tyrosine kinase activity and signal transduction pathways to regulate cell proliferation. EGFR amplification, which is rare in secondary glioblastomas, occurs in 40% of primary glioblastomas and results in overexpression of the EGFR protein [60, 61]. 20–50% of glioblastomas with EGFR amplification have a mutated form, EGFRvIII, which codes for a tumour-specific truncated and constitutively active auto-phosphorylated receptor with tyrosine kinase activity and may confer an unfavourable prognosis [25, 62]. EGFR and EGFRvIII are potentially important targets for biological therapy in glioblastomas.

The most common genetic change seen in oligodendrogial tumours is a combined loss of chromosome arms 1p and 19q observed in the majority of oligodendroglomas (50–80%) irrespective of grade [33, 51], suggesting this is an early event in the development of these tumours. This genetic alteration arises through an unbalanced centromeric translocation between chromosomes 1p and 19q, resulting in complete loss of the 1p and 19q arms [63]. Loss of 1p and 19q is uncommon in other gliomas and is now considered the genetic hallmark of oligodendrogloma [64]. However, it is important to distinguish tumours with the 1p/19q codeletion from those with an oligodendrogial phenotype and 1p partial deletions, typically 1p36, which occur in astrocytic tumours and are associated with poor prognosis [65]. Complete loss of 1p and 19q is associated with good prognosis, prolonged survival [46, 66, 67] and sensitivity to chemotherapy, and radiotherapy has shown to be a better predictor of response to therapy and overall survival than conventional histopathology [31, 68–71]. Genetic testing for combined losses of 1p and 19q is now being used clinically to distinguish tumours of oligodendrogial and astrocytic genetic lineages, as a predictive and prognostic marker, and in the stratification of clinical trials. Similar to astrocytomas, progression to anaplasia in oligodendroglial tumours is associated with genetic alterations that regulate cell cycle control, including Rb1, CDKN2A, CDKN2B and p14ARF, but TP53 mutations and gene amplifications are rare [33, 72]. These tumour suppressor genes are frequently silenced in oligodendroglial tumours by promoter hypermethylation [73]. Loss of 10q occurs in approximately 10–20% associated with poor prognosis [31, 33, 46, 74], and occasionally PTEN mutation is observed [74]. Additional genetic alterations include gains on chromosomes 7 and 15q, and losses on 4q, 6p, 9p, 11, 13q, 18 and 22q [33, 75]. Oligoastrocytomas can be divided into two groups, those with loss of 1p and 19q resembling oligodendroglomas (~50%), or those with loss of 1p and TP53 mutation typical of astrocytomas (~33%) [33, 76], suggesting a clonal origin of these tumours [77, 78]. Anaplastic oligoastrocytomas show similar genetic alterations to anaplastic tumours of the oligodendrogial or astrocytic lineages [33, 51].

O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that removes alkyl groups from the O6 position of guanine in DNA following alklylation and methylation by agents such as nitrosoureas and temozolomide. The MGMT gene, at 10q26, is silenced by epigenetic hypermethylation of the gene promoter in approximately 50% of glioblastomas [79], whereas more frequent and extensive methylation is found in oligodendrogial tumours with 1p/19q loss [80]. The consequent reduction in MGMT expression is now believed to contribute to chemosensitivity. Glioblastomas with MGMT promoter hypermethylation are more likely to have longer survival when treated with concurrent temozolomide and radiotherapy [79], while recent research suggests the extent of methylation may influence survival [81]. Tumours with MGMT promoter hypermethylation are more likely to show radiation or treatment-induced pseudoprogression immediately after treatment, which is difficult to distinguish from disease progression by conventional MRI [82, 83].

More recently, through whole-genome sequencing, heterozygous point mutations were found in the IDH1 gene in 12% glioblastomas associated with younger age, secondary glioblastomas and increased survival [84]. IDH1 on chromosome 2q33, encodes isocitrate dehydrogenase 1, which catalyses the oxidative carboxylation of isocitrate to α-ketoglutarate, resulting in the production of cytosolic nicotinamide adenine dinucleotide phosphate (NADPH). All of the mutations were at codon 132, which lies within the active site, with the majority being a guanine to adenine transition resulting in the amino acid substitution of arginine to histidine (IDHR132H), which impairs the enzyme’s affinity for its substrate through heterodimer formation and dominantly inhibits wild-type IDH1 activity. Mutations in IDH1 confer tumour suppressor activity and contribute to tumourigenesis through induction of the hypoxia-inducible factor 1 (HIF-1) pathway [85]. Point mutations in IDH1 and less commonly in the related IDH2 gene (at codon 172) are frequently found in diffusely infiltrating gliomas and are rare in all other central nervous system (CNS) and non-CNS tumours [86]. IDH1 mutations are found in ~68, 74 and 77% of grades II and III astrocytomas, oligodendrogliomas and oligoastrocytomas, respectively and in secondary glioblastomas that develop from these lower grades tumours [87–90]. The gene mutation appears to be an early event in gliomagenesis, occurring before the acquisition of TP53 mutation or 1p/19q loss [90]. IDH1/IDH2 mutations are tightly correlated with co-deletion of 1p/19q and MGMT methylation, but are uncommon in tumours with EGFR amplification [91]. IDH1/IDH2 mutations are present in 78% secondary glioblastomas but only 5% of primary glioblastomas [87–90], and are associated with favourable prognosis in grade III astrocytomas and glioblastomas, and in WHO grades II, III and IV gliomas [89, 91, 92].

Classification of gliomas into molecular subtypes may be based not only on DNA-based genetic alterations, but also on transcription profiles through genome-wide
gene expression microarrays using RNA extracted ideally from snap frozen tumour tissue. Gene expression profiles have identified clinically relevant subgroups of gliomas [49, 50], distinguished oligodendroglial tumours with 1p/19q loss from those with intact 1p/19q [93, 94], and between primary and secondary glioblastomas [95] and identified expression profiles associated with good prognosis [96–99].

Paediatric gliomas

Although gliomas account for around 12% of cancers in children under 15 years of age, relatively few studies have been performed on their molecular characteristics [100]. Low-grade gliomas (LGGs), most of which are juvenile pilocytic astrocytomas (JPA), constitute the majority and specific variants are associated with heritable diseases. Neurofibromatosis 1 (NF1) is caused by mutations within the neurofibromin gene located on chromosome 17q. In up to 15% of cases NF1 is associated with LGG of the optic tract and hypothalamus [101, 102]. This suggests a role for NF1 or its signal transduction pathway (the mitogen-activated protein kinase (MAPK) pathway) in the development of sporadic JPA through ras inhibition, but this has not been proven. Chromosomal copy number changes are found in a proportion of pilocytic astrocytomas, but genetic alterations were more frequent and extensive in those older than 15 years [103]. Recently the MAPK pathway has been implicated in the tumourigenesis of pilocytic astrocytomas. Jones et al [104] demonstrated a novel tandem duplication at locus 7q34 leading to the fusion of KIAA1549 and BRAF in 66% of pilocytic astrocytomas. This in combination with wild-type IDH1/2 has been shown to distinguish pilocytic astrocytomas from grade II astrocytomas at a molecular level [105]. Tandem duplication at 3p25 leading to MAPK activation through a fusion between SRGAP3 and RAF1 has been reported in approximately 2% of pilocytic astrocytomas [106]. Low-grade astrocytoma is also a feature of Li–Fraumeni syndrome, which is triggered by a TP53 germline mutation. TP53 mutations are found in up to 19% of sporadic grade II diffuse paediatric astrocytomas [107]. Few other molecular genetic abnormalities have been identified in paediatric LGG. In particular EGFR gene amplification and overexpression of the protein is rarely seen [107]; however Tabori et al [108] showed a high rate of EGFR amplification and overexpression in tumours from children with LGG disseminated within the CNS.

In contrast to adults, little is known regarding the progression from low to high grade, as malignant transformation is rare (<10%). A recent study by Broniscer et al [109] investigated 11 patients with progression from a previous LGG. Small numbers of assessable patients precluded any statistically significant conclusions but p53 overexpression was observed more frequently after transformation and PTEN deletion was found after transformation in over 50%. De novo high-grade astrocytomas are much less common in children, and their molecular abnormalities are reminiscent of secondary glioblastoma in adults [110]. The mechanisms of tumourigenesis in children are distinct from those in adults as evidenced by the presence of other genetic differences, the rarity of progression in the paediatric group and recent studies using comparative genomic hybridisation [111]. Various genetic pathways have been implicated including p53, EGFR, Rb, PI3K, MGMT and mismatch repair (MMR). Overexpression of p53 and TP53 mutations are associated with adverse outcomes [110]. The former is found in one-third of paediatric patients and increases with tumour grade [110]. TP53 mutations are significantly less common in children under 3 years of age than in older children [112]. Paediatric HGGs infrequently show EGFR amplification, a common feature of adult de novo glioblastomas [113–115]. However, EGFR overexpression is present in up to 85% of paediatric supratentorial HGGs [113, 115]. RNA expression studies have shown overexpression of EGFR and other genes associated with angiogenesis [116]. The role of the Rb1 pathway in paediatric HGGs is not well characterised despite disruption being observed in the majority of adult HGGs. In particular p16 inactivation is only observed in 9% of paediatric tumours (50–70% adults) and CDK4 amplification in 6% of paediatric HGGs (15% in adults) [114]. PTEN mutations have been observed in 6% of paediatric anaplastic astrocytomas and 20% of glioblastomas and have been associated with reduced survival [114]. Donson et al [117] recently indicated that children with glioblastomas with methylated MGMT may also benefit from temozolomide, and this marker may be a prognostic factor for survival. Microsatellite instability is used as a surrogate marker for defects in MMR genes and has been found to be markedly more common in paediatric HGGs while being rarely exhibited in adult tumours [118]. Paediatric oligodendrogliomas and oligoastrocytomas are uncommon and their genetics has not been characterised extensively; however, 1p/19q loss is rarely seen [119].

Origins of glioma and stem cells

To date, neither histopathological classification nor molecular genetic characterisation has been able to adequately predict or account for the resistance displayed by the majority of gliomas to radiotherapy and chemotherapy and the early recurrence of those that do respond to therapy. The cellular origin of gliomas remains a topic of debate. One hypothesis is that gliomas arise from neoplastic transformation and dedifferentiation of mature glial cells, astrocytes, oligodendrocytes and ependymal cells, giving rise to tumours resembling these cells [15, 120]. However, evidence to support this mechanism of gliomagenesis is limited and does not account for mixed gliomas. Alternatively, the cancer stem cell hypothesis suggests tumour cells with stem-cell like properties are present within tumours and are responsible for their initiation and continued repopulation. It was previously thought the only dividing cells within the adult brain were glial cells. It is now known there are both neural stem cells and glial progenitor cells in multiple regions of the adult brain, including the subventricular zone (SVZ), the dentate gyrus, hippocampus and subcortical white matter [121–125]. Self-renewing neural stem cells are able to divide asymmetrically [126] and their progenitors are capable of differentiating along either neuronal or glial lineages to produce mature...
differentiated cells [121, 123]. Neural stem cells and glial progenitor cells have migratory potential and there is increasing evidence that neoplastic transformation of these cells gives rise to the various types of glioma [121, 127] (Figure 4). Gene expression research supports the concept that histologically similar tumours may be molecularly distinct because they arise from distinct populations of site-restricted progenitors [128]. In addition, MRI studies suggest the spatial relationship of glioblastomas with the SVZ may influence invasiveness and patterns of recurrence [129]. Brain tumour stem cells, which are also referred to as brain tumour-initiating cells or brain tumour stem-like cells (BTSCs), have been identified in glioblastomas [130, 131], low-grade astrocytomas [132], anaplastic oligoastrocytomas [133], ependymomas [134] and established cell lines [135] on the basis of their ability to grow as neurospheres in vitro and/or expression of stem cell markers, such as CD133 (prom1), nestin and musashi-1. These BTSCs, present and/or expression of stem cell markers, such as CD133 (prom1), nestin and musashi-1. These BTSCs, present as only a minor subset of the total tumour population, are capable of self-renewal, i.e. generate new stem cells by either asymmetric or symmetric cell division, and generate new tumours when orthotopically transplanted into immune-compromised mice [132, 136]. BTSCs are particularly chemo- and radioresistant [137–139], possibly owing to their increased capacity to repair DNA damage [140], and expression of drug transporters [141, 142]. BTSCs contribute to tumour angiogenesis [143], while the tumour vascular microenvironment regulates BTSC behaviour [144]. There is increasing evidence that therapeutic resistance is due to the presence of stem cells within gliomas and these cells should be a key therapeutic target for eradication of the tumour [145]. Gene expression profiling has been used to identify cell signalling pathways active in stem cells derived from glioblastomas [146] and ependymomas [134]. Stem cell-related "self-renewal" gene expression signatures have been associated with resistance to concomitant chemoradiotherapy also in glioblastomas [97]. Such research is essential for the identification of therapeutic targets to eliminate cancer stem cells. By the same context, future imaging research should be directed to the development of imaging biomarkers associated with the presence of stem cells within gliomas.

**Glioma biology and imaging**

**Histological grade**

The histological features used to classify gliomas are reflected macroscopically in their imaging characteristics, which may be used as a non-invasive tool to distinguish tumour from normal brain and to predict grade and thereby prognosis. The proliferation rate of gliomas, reflected in their mitotic index and frequently measured immunohistochemically by labelling S-phase cells via the Ki-67 or MIB-1 antigens, increases progressively from low to high grade. This increased cell division is associated with elevated choline signal in proton magnetic resonance spectroscopy (MRS), reflecting cell membrane phospholipid turnover [147] and increased uptake of amino acids and glucose in PET [148]. Increased cellularity in HGGs results in fewer neurones within tumour tissues and a decreased N-acetylaspartate signal in MRS [147, 149], as well as decreased apparent diffusion coefficient (ADC) in diffusion-weighted imaging, reflecting more solid tissue with decreased water mobility [9, 150]. High growth rates in HGGs necessitate increased metabolism, which becomes anaerobic as growth outstrips oxygen supply, and hypoxia and necrosis result, associated with elevated lipid and lactate signals in MRS [9, 10].

The vasculature is a key feature in the histopathology diagnosis of gliomas and permits imaging associations with grade through perfusion-weighted imaging. The vessels within tumour tissue in LGGs may be somewhat more numerous than in normal brain and may adopt "chicken-wire" patterns in oligodendrogliomas, but vessel structure is unaltered and the blood–brain barrier remains intact. Neovascularisation in gliomas is associated with malignant transformation and biological aggressiveness, resulting through angiogenesis, intussusception and vessel co-option regulated by secretion of endothelial growth factors in response to hypoxia and degradation and remodelling of extracellular matrix macromolecules, leading to loss of blood–brain barrier integrity [151, 152]. Vessels in glioblastomas are tortuous,
disorganised and highly permeable, with larger lumens and abnormalities in the vessel wall, pericyte coverage and basement membrane. Aberrant microvasculature typically appears as “glomeruloid tufts” consisting of multilayered, mitotically active endothelial cells and perivascular cells [26, 152]. However, these changes are not uniform, leading to considerable spatial and temporal phenotypic heterogeneity in blood vessel architecture within HGCs, which is reflected in perfusion-weighted MRI. The distinction of tumour tissue from normal brain and between gliomas of different grade has been demonstrated by a variety of perfusion parameters. These include relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF) and contrast transfer coefficient ($K^\text{trans}$), which measures vascular permeability [10, 11, 153, 154].

**Molecular subtypes of glioma**

The application of molecular genetic markers to classify gliomas has led to investigations comparing the imaging characteristics of molecular subgroups.

**1p/19q genotype**

As described above, oligodendrogial tumours are typified by 1p/19q loss, whereas astrocytomas are more likely to have TP53 mutation and loss of 17p, providing a more robust means to distinguish oligodendrogliomas from astrocytomas than conventional histopathological classification. This has prompted numerous studies to investigate whether imaging might provide a non-invasive means to distinguish these genetic subtypes. A preferential distribution of oligodendrogial tumours with TP53 mutation to the temporal lobe and those with 1p/19q to the frontal, parietal and occipital [155, 156] or frontal [157] lobes or non-temporal locations [76] has been reported. However, other studies found no significant differences between genotype and tumour location [46, 67, 158]. In conventional MR studies oligodendrogliomas with 1p/19q loss were more likely to have indistinct borders on $T_1$ weighted images, mixed signal intensities on $T_1$ and $T_2$, paramagnetic susceptibility effect and calcification [14]. However, $T_1$ and $T_2$ signal inhomogeneity was associated with intact 1p/19q in oligoastrocytomas [76]. In a similar study of oligodendrogial tumours diagnosed by frame-based serial stereotactic biopsy, assessment of *in vivo* histological growth patterns in relation to co-registered clinical imaging characteristics showed tumours with intact 1p/19q were more likely to have an infiltrative growth pattern [12]. Transition in cellularity across the tumour margin was similar irrespective of genotype; however, those with a sharp/smooth border on $T_2$ weighted imaging (Figure 5a,b) and homogeneous signal intensity on $T_1$ and $T_2$ were more likely to have intact 1p/19q [12]. To provide a more objective method to assess differences in imaging characteristics, Brown et al [159] have used a quantitative method of MR analysis based on an S-transform to measure image texture in a series of low-grade oligodendrogial tumours in relation to genotype (Figure 6). Differences in texture were seen between tumours with 1p/19q loss and those with intact 1p/19q on contrast-enhanced $T_1$ and $T_2$ weighted MRI, enabling non-invasive discrimination of genotype with high sensitivity and specificity. The biological basis of these differences in imaging characteristics on anatomical MRI is as yet unknown, although Megyesi et al [14] postulated that differences in signal intensity and tumour borders may be due to increased “invasiveness” in tumours with loss of 1p/19q.

Distinction between oligodendrogial genotypes has also been observed using multimodal advanced MRI. Using dynamic susceptibility contrast MRI (DSC-MRI) in a study of 37 oligodendrogial neoplasms, tumours with 1p/19q loss were more likely to have high rCBV than those with intact 1p/19q (Figure 5c,d) with receiver operating characteristic analysis revealing a cut-off of 1.59 for identifying genotype with sensitivity 92% and specificity 76% [160]. In this study rCBV was determined by placing regions of interest over areas of highest blood volume to derive rCBV$_{\text{max}}$. Subsequently elevated rCBV in association with 1p/19q loss has been supported in other small series of oligodendrogial tumours measuring rCBV [161–163] or using histogram analysis [164]. These data warrant further study in larger series to determine the potential of rCBV measurements for the non-invasive prediction of genotype. In histopathology comparisons, rCBV was higher in low-grade oligodendrogliomas than astrocytomas [165], but similar in some, but not all studies, of low and high grade oligodendrogliomas [166, 167], rendering DSC-MRI-based tumour grading potentially inaccurate [160, 166, 168]. Therefore, unlike astrocytomas, high rCBV measurements may not be indicative of aggressive biology in oligodendrogial tumours with 1p/19q loss, suggesting differences in the baseline biology of the two genetic subtypes of glioma. These differences may be attributable to the elevated microvessels density seen in both low- and high-grade oligodendrogliomas and may reflect their “chicken wire” vasculature [169, 170]. In diffusion MRI, ADC has been shown to vary according to 1p/19q status [171]. Oligodendrogial tumours with intact 1p/19q were more likely to have a higher maximum and histogram ADC and a greater ADC transition coefficient (ATC) (Figure 5e,f). Similarly, Tozer et al [172] have reported that low-grade oligodendrogliomas had a lower ADC histogram than astrocytomas. These differences may reflect the cellularity of these tumours, as astrocytomas have a tendency towards lower cell density and to be more cystic than oligodendrogliomas, whereas tumours with intact 1p/19q are more likely to show infiltrative growth patterns [12]. Alternatively differences in ADC may reflect the extracellular matrix composition of these tumours; indeed, a recently published study of oligodendrogial genotype failed to demonstrate any relationship between a quantitative assessment of cellularity and ADC [173].

In contrast, to perfusion and diffusion MRI, oligodendrogial tumours with 1p/19q loss could not be distinguished from those with intact 1p/19q using routine clinical MRS and measurement of N-acetalspartate, choline, myoinositol or lipid and lactate metabolite ratios [174]. However, in another study, lipid, lactate, glutamine and glutamate metabolite ratios distinguished low-grade oligodendrogliomas from astrocytomas [175].

Metabolic imaging with radiolabelled tracers has been used in a number of glioma studies to yield diagnostic or
prognostic information [148], but few studies have so far related metabolism to genotype. Brain tumour metabolism was assessed by single-photon emission CT (SPECT) in oligodendrogial neoplasms characterised by genotype using thallium-201 (201Tl) and [18F]-fluorodeoxyglucose (FDG) [42]. 201Tl has a low uptake in normal cerebral tissue because of restricted passive diffusion across the blood–brain barrier. Its uptake in gliomas is thought to depend on disruption of the blood–brain barrier and activity of the Na/K ATPase pump, indicating cell viability and to a lesser extent blood flow. FDG, an analogue of glucose, is transported into the cell by facilitated diffusion, where it is subsequently phosphorylated by hexokinase to fluoroglucose-6-phosphate, but unlike glucose, this is not a substrate for further metabolism and becomes trapped intracellularly. There was a positive correlation between 201Tl and FDG uptake, and between metabolic rate and both histological grade and contrast enhancement, although some low-grade oligodendrogial tumours showed high metabolism. There was a clear association between metabolism and genotype. Oligodendrogial tumours with 1p/19q loss were more likely to show increased 201Tl uptake and, to a lesser extent, increased FDG uptake than those with intact 1p/19q [42]. In support of these observations, other studies report high FDG metabolic activity in low-grade oligodendrogliomas [176, 177]. Stockhammer et al [178] have recently investigated FDG uptake by PET and shown raised glucose utilisation in six

Figure 5. Multimodal imaging characteristics of oligodendrogial tumours classified by genotype. (a, b) T2 weighted MRI. (c, d) Negative enhancement integral colour maps used to derive relative cerebral blood volume (rCBV). (e, f) Apparent diffusion coefficient (ADC) maps. The left panel shows 1p/19q loss tumours exhibiting indistinct, (a) irregular T2 border, (c) high rCBV and (e) low histogram ADC. The right panel shows 1p/19q intact tumours displaying sharp, (b) smooth T2 border, (d) low rCBV and (f) high histogram ADC.
of eight grade II gliomas with 1p/19q loss compared with zero of eight with intact 1p/19q. In a case study, a spinal oligoastrocytoma with 1p/19q loss had high glucose uptake [179]. These data suggest increased metabolic activity in oligodendroglomas with 1p/19q loss. In summary, imaging data have revealed differences between gliomas of astrocytic and oligodendroglial genetic lineages that must reflect differences in their biology, but which are as yet poorly understood. In addition non-invasive imaging molecular diagnosis of oligodendroglomas may potentially have future clinical utility.

**Primary and secondary glioblastomas**

Evidence that molecular subtypes of glioblastoma may be distinguished by MRI is emerging. Aghi et al [180] categorised glioblastomas according to EGFR amplification (primary glioblastomas) and mutations in exons 5–8 of the TP53 gene (secondary glioblastomas) and compared this to four imaging variables: (a) $T_2/T_1$, the ratio of $T_2$ bright volume to enclosed $T_1$ enhancing volume; (b) percentage of tumour volume that was necrosis; (c) and (d) $T_1$ and $T_2$ border sharpness coefficients (BSCs). The percentage necrosis and $T_1$ BSC did not differ between glioblastoma subtypes, but EGFR-amplified tumours had increased $T_2/T_1$ ratio and decreased $T_2$ BSC, suggesting increased angiogenesis, oedema and/or invasion through alterations in EGFR signalling pathways in EGFR-overexpressing tumours (Figure 7). EGFR-amplified tumours exhibit elevated oedema, possibly through EGFR activation of hypoxia-inducible transcription factor, potentially resulting in increased angiogenesis, due to increased secretion of vascular endothelial growth factor (VEGF) and increased invasion of surrounding normal brain, possibly due to matrix metalloproteinase activity [116, 181–183]. In a similar study, imaging characteristics of glioblastomas were correlated with expression of the p53 protein measured immunohistochemically. Tumours with greater than 50% of cells showing p53 immunopositivity were more likely to show ring enhancement and well-defined borders on $T_1$ weighted images with contrast than tumours with lower proportions of p53-positive cells [184]. Glioblastomas with unmethylated MGMT were more likely to show ring enhancement and differed from MGMT methylated tumours in texture analysis using S-transform [185]. These data support the distinction of molecular subtypes of glioblastoma through conventional MRI.

**Gene expression and imaging**

Many imaging studies have sought to explain the imaging findings in terms of the histopathological and biological characteristics of the tumour tissue. For example [$^{11}$C]-methione uptake measured by PET correlated with the proliferative activity measured immunohistochemically in LGGs [186] and rCBV correlated with tumour grade and the expression of VEGF in non-enhancing gliomas [187]. However, most studies suffer
Figure 7. Border sharpness coefficient (BSC) in glioblastomas. The tumour shown in (a) had the largest $T_2$ BSC, signifying a sharp $T_2$ bright border, and proved to be non-epidermal growth factor receptor (EGFR)-amplified, whereas the tumour in (b) had the smallest $T_2$ BSC, signifying a fuzzy $T_2$ bright border, and proved to be EGFR-amplified. Reproduced with permission from Aghi et al. [180].

Figure 8. Gene expression surrogates for MRI traits. (a) Association between the hypoxia gene expression module and contrast enhancement. Tumour arrays were clustered by using only cDNA clones contained within the gene module. The value of the imaging trait for each tumour is indicated by the coloured box above the expression map. Representative MRI are depicted on the left and a subset of named genes is labelled. (b) Expanded view of the association between the proliferation gene-expression module and mass effect. Reproduced with permission from Diehn et al [13].
the limitation that imaging and histology are likely to be heterogeneous and the sample analysed may not be from the tumour region from which imaging signatures are derived. Additionally, most studies have used a candidate approach, looking only at specific aspects of histology, biology or expression of single gene markers. These limitations are now being addressed through image-guided sample acquisition and expression profiling studies. Using computer-assisted frameless navigation to obtain samples from tumour regions with defined imaging characteristics, Hobbs et al [188] demonstrated differences in the protein expression profiles from enhancing and non-enhancing tumour regions. Similarly van Meter et al [189] obtained image-guided biopsy specimens from the tumour core and enhancing periphery of untreated glioblastomas and used microarray gene expression profiling to demonstrate intratumoural regional differences in molecular phenotype, with many of the genes identified as differentially expressed being potential therapeutic targets, e.g. EGFR, VEGF and matrix metalloproteinases. More recently, upregulation of genes associated with hypoxia, angiogenesis and oedema was observed in biopsies from completely enhancing compared with incompletely enhancing glioblastomas [190]. In another similar study, Barajas et al [191] showed differences in rCBV and ADC between enhancing and non-enhancing peritumoural regions in glioblastomas and in the gene expression profiles of biopsies obtained from these regions, with upregulation of biological processes associated with mitosis, angiogenesis and apoptosis within contrast-enhancing regions. Diehn et al [13] have combined neuroimaging and microarray analysis to create a multidimensional map of gene expression patterns in glioblastoma that provided clinically relevant insights into tumour biology. Tumour contrast enhancement and mass effect predicted activation of specific hypoxia and proliferation gene-expression programmes, respectively (Figure 8), and an infiltrative imaging phenotype was identified that predicted shorter survival. These studies demonstrate the association of complex molecular signatures with readily identifiable imaging characteristics.

Conclusion

In summary, molecular pathology research and advances in non-invasive multimodal imaging techniques have greatly increased our understanding of the relationship between genotype and histological and imaging phenotypes in diffusely infiltrating gliomas. Further research is important to develop the clinical potential for non-invasive multimodal MRI techniques to discriminate histological and molecular subtypes of glioma, and to decipher the molecular processes giving rise to macroscopic imaging characteristics, which are essential for the development of new imaging biomarkers and discovery of new clinically relevant therapeutic targets.

References

1. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer 2005;92:241-5.
Biology, genetics and imaging of glial cell tumours


